He X, Tian T, Ma Y
… +4 more, Cai Q, Deng G, Zhang X, Liang N
J Cancer Res Ther
· 2026 May · PMID 42241159
·
Publisher ↗
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. As resistance to EGFR-TKIs is ass...Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have become the standard first-line treatment for advanced non-small-cell lung cancer (NSCLC) with EGFR mutations. As resistance to EGFR-TKIs is associated with significantly worse prognosis, there is a critical need to understand the mechanisms underlying resistance and to develop effective subsequent treatment strategies. Immune checkpoint inhibitors (ICIs) show remarkable efficacy in treating solid tumors, including melanoma, esophageal cancer, and NSCLC. The role of immunotherapy in EGFR-TKI-resistant cases has generated varied perspectives among researchers. This article reviews findings on the interplay between EGFR, the tumor microenvironment, and ICIs, as well as recent advances in post-EGFR-TKI resistance treatment strategies. By doing so, this review aims to provide insights for research and clinical management of EGFR-TKI-resistant NSCLC.
Lou Y, Zhou H, Liu F
… +11 more, Chang R, Chen Z, Dong C, Liu J, Tang X, Yang Q, Lu C, Yu H, Fu D, Ma Y, Wu W
J Cancer Res Ther
· 2026 May · PMID 42241158
·
Publisher ↗
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and prevalent malignancy challenged by early detection, frequent presentation at advanced stages, and high likelihood of postoperative recurrence and metasta...Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and prevalent malignancy challenged by early detection, frequent presentation at advanced stages, and high likelihood of postoperative recurrence and metastasis. Despite ongoing research efforts, the 5-year survival rate for PDAC has only marginally improved. Although pharmacotherapy remains the cornerstone of multidisciplinary management strategies for PDAC, treatment options for advanced disease have historically been limited. In recent years, an increasing number of clinical trials have identified novel agents and combination therapies with promising efficacy for advanced PDAC. Immunotherapy has demonstrated significant success across various solid tumors, yet application for PDAC has so far yielded limited clinical benefit. Combination approaches integrating immune checkpoint inhibitors with chemotherapy, radiotherapy, and other therapeutic modalities have shown preliminary evidence of efficacy, although further investigation is necessary. Emerging immunotherapeutic strategies, such as adoptive cell transfer, oncolytic virotherapy, and tumor vaccines, have exhibited potential for PDAC treatment, albeit accompanied by inherent limitations. Hence, a more thorough understanding of the complex tumor microenvironment in PDAC is essential to improve the effectiveness of immunotherapeutic interventions. Personalized and precision-driven combination immunotherapies represent a promising frontier in the future of PDAC treatment. This review outlines recent advances and future perspectives in immunotherapy for PDAC, aiming to inform and enhance therapeutic strategies for this devastating malignancy.
Liu X, Wang J, Zhang H
… +38 more, Xu X, Wang X, Wang L, Zhou H, Wang Q, Sun Z, Shao L, Cao YJ, Huang H, Li Z, Li Y, He Y, Xia Z, Liu J, Zhang X, Qu R, Liu Y, Suo Z, Hou T, Yu Z, Xu Z, Chen P, Ren H, Nie D, Huang Z, Li G, Meng J, Deng L, Liu L, Dai W, He M, Zhou Z, Wang D, Xiao J, Jin M, Liu Z, Guo Z, China Collaborative Group on Research and Transformation of Infection Immunity and Microecology
J Cancer Res Ther
· 2026 May · PMID 42241157
·
Publisher ↗
Hematopoietic stem cell transplantation (HSCT) is used to treat various hematologic diseases, including autologous and allogeneic transplants. As the indications for HSCT have expanded and its clinical application has be...Hematopoietic stem cell transplantation (HSCT) is used to treat various hematologic diseases, including autologous and allogeneic transplants. As the indications for HSCT have expanded and its clinical application has become more widespread, it is essential to ensure standardized and appropriate use of techniques. A comprehensive assessment of HSCT is an important step in clinical decision-making. To standardize diagnosis and treatment in HSCT clinical practice, an expert panel from the Chinese Collaborative Group on the Transformation of Infectious Immunology and Microecology Research participated in this evaluation to provide guidance for the management of HSCT in clinical practice.
Guo F, Liu L, Sun Y
… +3 more, Jin Z, Miao Y, Ma Y
J Cancer Res Ther
· 2026 May · PMID 42241156
·
Publisher ↗
Ovarian cancer (OC) is among the most prevalent malignant tumors of the female reproductive system. Its high mortality rate is strongly associated with the development of chemotherapy resistance, making research into res...Ovarian cancer (OC) is among the most prevalent malignant tumors of the female reproductive system. Its high mortality rate is strongly associated with the development of chemotherapy resistance, making research into resistance mechanisms critical for improving patient outcomes. In recent years, ferroptosis, an iron-dependent form of cell death, has garnered significant attention in tumor resistance research due to its unique regulatory mechanisms. Studies indicate that ferroptosis contributes to OC resistance by modulating pathways including lipid peroxidation, iron metabolism, and antioxidant systems; however, its precise molecular mechanisms remain incompletely elucidated. Furthermore, the interaction between ferroptosis and resistance to conventional chemotherapy agents in OC has emerged as a research hotspot. This systematic review examines the fundamental characteristics of ferroptosis and its potential mechanisms in OC resistance, while exploring therapeutic strategies targeting ferroptosis-related pathways to reverse drug resistance. By synthesizing existing research advances, this paper aims to provide new theoretical foundations to deepen our understanding of OC resistance mechanisms and to suggest potential directions for developing novel targeted therapeutic approaches.
J Cancer Res Ther
· 2026 May · PMID 42241155
·
Publisher ↗
Due to high morbidity and mortality rates, colorectal cancer (CRC) poses the significant global health challenge, thus early screening is essential to improve patient outcomes. DNA methylation biomarkers have become pivo...Due to high morbidity and mortality rates, colorectal cancer (CRC) poses the significant global health challenge, thus early screening is essential to improve patient outcomes. DNA methylation biomarkers have become pivotal tools for detection of CRC, moving from research to clinical use. Key methylation loci (SEPT9, BMP3, and NDRG4) have been identified through genome-wide association studies and candidate gene approaches, then validated with high-throughput technologies, such as methylation arrays and next-generation sequencing. This advancement has led to the creation of clinically approved assays. Notably, the sensitivity of the Cologuard assay for detection of CRC is 92%, while that of the Epi proColon assay is 70%-80%, both outperforming traditional methods like fecal immunochemical testing, which has a sensitivity of 74%. These assays offer non-invasive screening for both average- and high-risk groups, and aid in postoperative monitoring. However, significant challenges remain. Key issues include technical difficulties for detection of low-abundance methylation signals and standardization of sample processing methods. Clinically, managing false results and validating long-term efficacy are problematic. Ethical concerns about overdiagnosis and data privacy also require attention. Future efforts should prioritize technological advancements, like single-molecule sequencing and liquid biopsy integration, along with large-scale prospective studies to validate biomarker utility in diverse populations. Updated guidelines for standardized implementation are also crucial. This review underscores the pivotal role of methylation biomarkers to revolutionize screening of CRC, while stressing the need for interdisciplinary collaboration, and outlines a strategy to address current limitations, ultimately aiming to reduce the global impact of CRC.
J Cancer Res Ther
· 2026 May · PMID 42241154
·
Publisher ↗
Selective internal radiotherapy (SIRT) has emerged as a viable treatment for both primary and secondary liver neoplasms, exhibiting favorable efficacy and low toxicity in clinical applications. This review synthesizes ke...Selective internal radiotherapy (SIRT) has emerged as a viable treatment for both primary and secondary liver neoplasms, exhibiting favorable efficacy and low toxicity in clinical applications. This review synthesizes key studies that investigate the safety and efficacy of SIRT, particularly in hepatocellular carcinoma and intrahepatic cholangiocarcinoma, along with its application in treating liver metastatic malignancies. SIRT demonstrates superior time to progression, enhanced quality of life, and reduced toxicity compared with conventional therapies, including tyrosine kinase inhibitors and transarterial chemoembolization, despite comparable overall survival benefits. Notwithstanding these gains, additional study is warranted to enhance combination therapy, improving dosimetry models. Further investigation is also needed to explore the use of SIRT in extrahepatic cancers. Personalized dosimetry holds significant potential for improving patient outcomes and warrants further exploration in several key areas, including biodistribution simulation, dosimetry calculation method refinement, intraprocedural visualization advancement, and posttreatment dosimetry evaluation technique improvement. Furthermore, the integration of SIRT with systemic therapies has demonstrated potential for synergistic effects, thereby enhancing tumor response and survival outcomes. SIRT is a significant enhancement to the treatment repertoire for liver neoplasms, with ongoing research further broadening its clinical applicability and improving patient outcomes.
Qiu B, Jiang Y, Lian Z
… +16 more, Xie Y, Wei T, Ji Z, Sun H, Xu F, Peng R, Wang H, Xue J, Li G, Wu G, Wang E, Zhang H, Xu B, Liu S, Duan X, Wang J
J Cancer Res Ther
· 2026 May · PMID 42241153
·
Publisher ↗
Stereotactic ablative radiotherapy (SABR) is increasingly administered in hepatocellular carcinoma (HCC) treatment. The CyberKnife (CK) system is the most advanced robotic radiosurgery system for delivering SABR. Using t...Stereotactic ablative radiotherapy (SABR) is increasingly administered in hepatocellular carcinoma (HCC) treatment. The CyberKnife (CK) system is the most advanced robotic radiosurgery system for delivering SABR. Using three-dimensional multi-angle irradiation, a unique fiducial marker, and a synchronous respiratory tracking system, the off-target caused by respiratory movement is maximally avoided, which achieves favorable dose conformation, and the dose rapidly drops off in the surrounding normal tissue. In a real sense, CK achieves accurate positioning, planning, and irritation. The Chinese expert consensus on CK for HCC was established after discussion.
Huang J, Yang P, Wang Z
… +3 more, Feng P, Fu Y, Li J
J Cancer Res Ther
· 2026 May · PMID 42204887
·
Publisher ↗
BACKGROUND: Distant metastases (DM) in differentiated thyroid carcinoma (DTC) are uncommon but markedly worsen patient prognosis. Existing risk prediction models frequently show limited accuracy because key clinicopathol...BACKGROUND: Distant metastases (DM) in differentiated thyroid carcinoma (DTC) are uncommon but markedly worsen patient prognosis. Existing risk prediction models frequently show limited accuracy because key clinicopathological predictors are not fully integrated. This study aimed to identify risk factors for DM and to develop a decision tree-based predictive model. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 15,591 patients with DTC who underwent initial surgery at three tertiary centers between 2000 and 2018. Thirty-seven patients with DM and complete clinicopathological data constituted Cohort 1 (training set), whereas 14 comparable cases formed Cohort 2 (validation set). A 4:1 ratio-matched control group was generated by random sampling of patients with postoperative no evidence of disease (NED), matched for age, sex, and year of surgery. RESULTS: Univariate and multivariate analyses demonstrated significant differences (P < 0.001) between the DM and NED cohorts in median age, extrathyroidal extension (ETE), AJCC stage, tumor location, histological subtype, and primary tumor diameter. Decision tree and random forest analyses identified AJCC stage and tumor diameter as the most influential predictors of DM. A predictive model incorporating these variables achieved perfect classification accuracy, which was confirmed through external validation. In cases with metachronous metastases, histological subtype and ETE independently predicted survival outcomes. CONCLUSION: This study statistically optimized the weighting of risk factors for DM prediction in DTC, emphasizing AJCC stage and tumor diameter as dominant determinants. The resulting model demonstrated high accuracy and may support clinical decision-making for personalized patient management as a risk stratification tool.
Tian G, Long S, He Y
… +6 more, Jin X, Chai W, Cheng C, Deng Z, Jiang T, Li L
J Cancer Res Ther
· 2026 May · PMID 42204886
·
Publisher ↗
BACKGROUND: Pulsed electric field (PEF) ablation is a promising nonthermal tumor treatment for liver cancer, recognized for its ability to induce immune responses. However, the field has lacked a comprehensive bibliometr...BACKGROUND: Pulsed electric field (PEF) ablation is a promising nonthermal tumor treatment for liver cancer, recognized for its ability to induce immune responses. However, the field has lacked a comprehensive bibliometric evaluation. This study aimed to provide an in-depth analysis of the research landscape. METHODS: In total, 691 English-language articles on PEF-based liver cancer therapy, published between 1989 and 2025, were identified from the Scopus and Web of Science databases. Bibliometric tools, including VOSviewer, CiteSpace, Scimago Graphica, and Bibliometrix, were applied to perform coauthorship, cocitation, and keyword cooccurrence analyses, focusing on contributions from countries, institutions, authors, and journals. RESULTS: Research on PEF therapy in liver cancer has grown steadily, showing an annual increase of 9.7%. The United States and China were the most influential contributors, with the former leading in both total publications and citations. Major contributing institutions included Zhejiang University, Zhongshan University, and Northwestern University, with Leen Edward, Nuccitelli Richard, and Davalos Rafael V. the most frequently cocited authors. Journal of Vascular and Interventional Radiology was the most productive journal in the field. Radiology showed the highest total link strength in cocitation analysis. Co-occurrence analyses of keywords and cocited references highlighted the tumor microenvironment and immunotherapy as emerging research priorities. CONCLUSIONS: PEF therapy for liver cancer is advancing rapidly and holds strong clinical promise. Future research will likely focus on the tumor microenvironment, immune mechanisms, and field parameter optimization. Strengthened international collaboration is essential to foster innovation and expand clinical applications.
Zheng Z, Bi G, Wu M
… +8 more, Yao G, Wang F, Sothea Y, Cheng J, Fan H, Yan Z, Wang X, Liu L
J Cancer Res Ther
· 2026 May · PMID 42041238
·
Publisher ↗
AIMS: This study aimed to compare the safety and effectiveness of cone-beam CT (CBCT)-guided thermal ablation vs video-assisted thoracic surgery (VATS) in patients with stage I-IIIA non-small-cell lung cancer (NSCLC). MA...AIMS: This study aimed to compare the safety and effectiveness of cone-beam CT (CBCT)-guided thermal ablation vs video-assisted thoracic surgery (VATS) in patients with stage I-IIIA non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 43 NSCLC patients underwent CBCT-guided thermal ablation, and 899 patients received VATS. After 1:1 propensity score matching (PSM), 32 patients were included in each cohort. Overall survival (OS), disease-free survival (DFS), recurrence rates, length of hospital stay, and complications were analyzed. RESULTS: The mean OS was 3.02 ± 1.31 years in the ablation group and 4.79 ± 2.87 years in the VATS group ( P = 0.08). The mean DFS was 2.30 ± 1.55 years and 4.34 ± 2.98 years, respectively ( P = 0.021). Local and distant recurrence occurred in five (15.6%) and seven (21.9%) patients in the ablation group, and in six (18.8%) and seven (21.9%) patients in the VATS group, with no significant difference in overall recurrence ( P = 0.595). The hospital stay was significantly shorter in the ablation group (3.67 ± 2.04 days) than in the VATS group (8.21 ± 3.68 days, P < 0.0001). The incidences of pneumothorax (P = 0.430), infection ( P = 0.086), pneumonia ( P = 0.554), and fever ( P = 0.230) were comparable between groups. CONCLUSION: CBCT-guided thermal ablation is a safe and effective treatment option for patients with stage I-IIIA NSCLC.
Ramdulari AV, Ravi A, Srivastava A
… +1 more, Pandey R
J Cancer Res Ther
· 2026 Jan · PMID 41910309
·
Publisher ↗
Sarcomas account for 1% of adult malignancies, and 80% of them arise from soft tissue. Orbital leiomyosarcoma is an extremely rare tumor with less than 40 cases reported. The most common subsite is the conjunctiva, follo...Sarcomas account for 1% of adult malignancies, and 80% of them arise from soft tissue. Orbital leiomyosarcoma is an extremely rare tumor with less than 40 cases reported. The most common subsite is the conjunctiva, followed by the eyelid. We present a case of orbital leiomyosarcoma, which presented with progressive prominence of the left globe. The patient was treated with surgery and postoperative radiotherapy. On the last follow-up, the patient is clinically disease-free. A review of the literature on patients with orbital leiomyosarcoma was done, out of which 84% of patients underwent surgery and 42% of patients received radiotherapy. 15% of patients had a childhood history of retinoblastoma (RB). All patients with childhood RB had bilateral disease and a history of childhood radiotherapy for retinoblastoma.
J Cancer Res Ther
· 2026 Jan · PMID 41910308
·
Publisher ↗
Neuroendocrine carcinomas (NECs) of the urinary bladder are rare, accounting for less than 1% of all bladder malignancies, and are characterized by aggressive behavior and poor prognosis. These tumors can occur as small...Neuroendocrine carcinomas (NECs) of the urinary bladder are rare, accounting for less than 1% of all bladder malignancies, and are characterized by aggressive behavior and poor prognosis. These tumors can occur as small or large cell subtypes and often mimic high-grade urothelial carcinoma, posing diagnostic challenges. We present five cases of bladder NECs diagnosed at our center, all presenting with hematuria and other lower urinary tract symptoms. Tumor sizes ranged from 4.8 to 7.5 cm, with all demonstrating deep muscle invasion and high proliferative index. Immunohistochemistry confirmed neuroendocrine differentiation. Four patients received platinum-based chemotherapy, and one underwent radical cystectomy. Two patients with advanced-stage disease succumbed early despite therapy. This series highlights the importance of early recognition, accurate histopathological diagnosis, and timely multimodal management. Given their rarity and diagnostic overlap with other high-grade bladder tumors, clinical awareness is crucial.
J Cancer Res Ther
· 2026 Jan · PMID 41910307
·
Publisher ↗
Sebaceous carcinoma (SC) typically arises in the periocular region but on rare occasions can present within the oral cavity, posing diagnostic and therapeutic challenges. This report describes a 50-year-old male who deve...Sebaceous carcinoma (SC) typically arises in the periocular region but on rare occasions can present within the oral cavity, posing diagnostic and therapeutic challenges. This report describes a 50-year-old male who developed a progressively enlarging ulcero-proliferative lesion in the right buccal mucosa, initially misdiagnosed as squamous cell carcinoma. Histopathological re-evaluation, supported by immunohistochemistry (CK5/6, p63, and epithelial membrane antigen positivity), established the diagnosis of SC, confirming sebaceous differentiation. Despite its atypical location, the tumor behaved aggressively, invading the mandible and necessitating a composite resection and neck dissection, followed by reconstruction with a pectoralis major myocutaneous flap. Postoperative recovery was uneventful, highlighting the efficacy of prompt surgical intervention when diagnosis is accurate. This case underscores the importance of considering SC among differential diagnoses for oral cavity lesions, especially when histological and immunohistochemical findings diverge from common oral malignancies. A collaborative effort among pathologists, radiologists, and surgeons remains critical for early detection, appropriate management, and improved patient outcomes.
Derqaoui S, Mesmoudi S, Znati K
… +1 more, Bernoussi Z
J Cancer Res Ther
· 2026 Jan · PMID 41910306
·
Publisher ↗
Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features is a recently described new entity, with only 4 cases reported in the English literature to date. It is characterized by the presence of a heman...Clear cell renal cell carcinoma (ccRCC) with hemangioblastoma-like features is a recently described new entity, with only 4 cases reported in the English literature to date. It is characterized by the presence of a hemangioblastoma-like component which shares the same morphologic and phenotypic features with renal hemangioblastoma associated to an unequivocal ccRCC component. Transition between both components is gradual. The diagnosis is challenging, especially when ccRCC component is scattered, the tumor might be diagnosed as a hemangioblastoma. In fact, distinguishing the latter from ccRCC with hemangioblastoma-like features is essential for providing patients with the best available treatments. In this article, we describe a new case of ccRCC with hemangioblastoma in a 30-year-old woman to raise awareness of this rare entity presenting a challenging diagnosis.
Pustake M, Kalas M, Valles-Gamez R
… +3 more, Eysha M, Didia SC, Gaur S
J Cancer Res Ther
· 2026 Jan · PMID 41910305
·
Publisher ↗
INTRODUCTION: Extramedullary leukaemia, also known as myeloid sarcoma, is a rare manifestation of acute myeloid leukaemia (AML) that typically occurs in conjunction with bone marrow involvement. It is characterized by in...INTRODUCTION: Extramedullary leukaemia, also known as myeloid sarcoma, is a rare manifestation of acute myeloid leukaemia (AML) that typically occurs in conjunction with bone marrow involvement. It is characterized by infiltration of leukemic cells into extramedullary tissues, including the skin, soft tissues, and lymph nodes, where it may present as mass-like or nodular lesions. When associated with high-risk cytogenetic abnormalities, extramedullary disease may exhibit particularly aggressive behaviour and pose substantial diagnostic challenges, especially when it precedes or masks systemic manifestations of AML. CASE DESCRIPTION: A 36-year-old postpartum woman, 6 months following delivery, presented with a 3-month history of progressively enlarging nodules involving the left side of the face. These lesions were initially attributed to a dental infection following extraction of two teeth; however, they persisted and progressed despite appropriate dental treatment. In the weeks preceding this presentation, the patient had developed worsening fatigue, dyspnoea, jaundice, and easy bruising. On examination, there were several firms, non-tender nodules over the left cheek, prominent left cervical lymphadenopathy, scleral icterus, and diffuse ecchymoses. Laboratory results showed pancytopenia with severe anaemia, thrombocytopenia, and neutropenia, elevated liver enzymes suggestive of systemic involvement. The initial differential diagnosis included chronic infection, granulomatous disease, and hematologic malignancy. Following this, imaging showed multifocal facial soft-tissue masses and extensive cervical lymphadenopathy. Core biopsy of a cheek lesion showed diffuse infiltration by atypical myeloid cells consistent with extramedullary AML with monocytic differentiation, which was confirmed on bone marrow biopsy. Cytogenetic analysis revealed a t(10;11)(p13;q13.3), an additional der (20) t(1;20)(q21;q13.3), and a marker chromosome. Induction chemotherapy with cytarabine and idarubicin was initiated. Following consolidation therapy, the patient developed new cutaneous nodules and plaques several weeks later, and skin biopsy confirmed leukaemia cutis, indicating persistent extramedullary disease. DISCUSSION: This case illustrates a rare and aggressive presentation of extramedullary AML with monocytic differentiation and high-risk cytogenetics in a young postpartum patient, initially mimicking a localized odontogenic infection. The delayed diagnosis underscores the complexity of recognizing extramedullary leukaemia, particularly when early hematologic abnormalities are subtle or absent. The presence of a t(10;11) translocation and the subsequent development of leukaemia cutis following induction therapy highlight the aggressive biologic behaviour of this disease and reinforce the importance of heightened clinical suspicion, prompt tissue diagnosis, and vigilant surveillance for extramedullary relapse, which may require intensified therapeutic approaches.
Chakravorty A, Purohit BN, Mittal A
… +2 more, Mohan V, Naithani R
J Cancer Res Ther
· 2026 Jan · PMID 41910304
·
Publisher ↗
The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-ce...The outcomes of elderly patients with lymphoma are poor. There is scarcity of data on outcomes of chemotherapy-free regimens in patients older than 80 years with a B-cell lymphoma. We report three octogenarians with B-cell NHL and the efficacy and safety of a nonchemotherapy regimen using a lower dose of polatuzumab vedotin and anti-CD20 monoclonal antibody. No infusion-related adverse events were noted. No patient developed neutropenia. Peripheral neuropathy was grade 2 in all cases. Recurrent UTI were a concern in two patients. After a median of 6 cycles (range 1-6) of polatuzumab therapy, all three patients had achieved CR. One patient was lost to follow-up and succumbed to a multidrug-resistant gram-negative UTI. One patient relapsed at 13 months and other is doing well in remission at 15 months.
J Cancer Res Ther
· 2026 Jan · PMID 41910303
·
Publisher ↗
Peritoneal surface malignancies (PSMs), such as pseudomyxoma peritonei, mesothelioma, and advanced metastases from ovarian, colorectal, gastric cancers, and sarcomatosis, are often categorized as terminal stage IV diseas...Peritoneal surface malignancies (PSMs), such as pseudomyxoma peritonei, mesothelioma, and advanced metastases from ovarian, colorectal, gastric cancers, and sarcomatosis, are often categorized as terminal stage IV diseases. Cytoreductive surgery (CRS) combined with Hyperthermic intraperitoneal chemotherapy (HIPEC) has revolutionized outcomes, improving five-year survival rates to 50%-60% in selected cohorts, with up to 15% of patients achieving cure. A central component of CRS is total peritonectomy, which demands extensive exposure of the abdominal and subdiaphragmatic surfaces. However, specialized retractors designed for this purpose are currently limited to costly international systems, priced between ₹15-50 lakhs, and are largely unavailable in resource-constrained regions. The RayTractAb-C system has been developed as a cost-effective, multipurpose, self-retaining retractor specifically designed for CRS and HIPEC. The device includes a modular rail clamp, adjustable horizontal rod with arms, and six curvilinear blades engineered for pelvic, abdominal, and chest wall retraction. This configuration enables simultaneous exposure of multiple compartments, reduces reliance on surgical assistants, and facilitates safer and more efficient peritonectomy. RayTractAb-C has demonstrated significant ergonomic and practical advantages during prototyping, with anticipated benefits in accessibility, cost reduction, and surgical independence. Further clinical evaluation is warranted to assess its role in standardizing CRS-HIPEC procedures across diverse surgical settings.
Noronha V, Sarkar L, Pillai A
… +17 more, Rao AR, Kumar A, Dhekale R, Mahajan S, Daptardar A, Sonkusare L, Vagal M, Mahajan P, Timmanpyati S, Gota V, Laskar S, Budrukar A, Swain M, Shetake A, Chowdhury OR, Pawar A, Prabhash K
J Cancer Res Ther
· 2026 Jan · PMID 41910302
·
Publisher ↗
OBJECTIVE: We aimed to evaluate characteristics and outcomes of patients with locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) planned for chemoradiation, and the role of geriatric assessment (GA) in deci...OBJECTIVE: We aimed to evaluate characteristics and outcomes of patients with locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) planned for chemoradiation, and the role of geriatric assessment (GA) in decision-making. METHODS: We included patients aged ≥60 years with LAHNSCC planned for chemoradiation referred to the geriatric oncology clinic between 2018 and 2023. RESULTS: Of 164 patients included, vulnerabilities were recorded in 36/148 (24.3%) patients assessed for functions and falls, 41/84 (48.8%) for comorbidities, 88/148 (55.4%) for nutrition, 26/148 (17.6%) for psychological, 6/87 (6.9%) for cognition, 25/84 (29.8%) for polypharmacy, and 8/148 (5.4%) for social domains. 76/148 (51.4%) were frail, with ≥2 vulnerabilities. 35 (21.3%) patients received radiotherapy alone; 117 (71.3%) patients received chemoradiation. Among 99 (86.4%) patients whose chemotherapy had not been planned prior to GA, chemotherapy regimen plan was changed after GA in 13 (13.1%). 24-month overall survival (OS) was 64.7% (95% confidence interval [CI]: 52.2%-80.3%). Factors significantly associated with poor OS were performance status (PS) ≥2 (hazard ratio [HR] 5.38, CI 2.39-12.1), vulnerability in nutrition (HR 2.52, CI 1.17-5.39), higher Cancer Aging and Research Group (CARG) chemotherapy toxicity score (HR 9.92, CI 3.91-25.16) and frailty (HR 10.51, CI 2.89-38.22). Factors associated with grade 3/4 toxicity included vulnerability in nutrition, higher CARG chemotherapy toxicity score and PS ≥2. CONCLUSION: Among older Indian patients with locally advanced head-and-neck squamous cell carcinoma planned for concurrent chemoradiation, 71.3% patients went on to receive concurrent chemotherapy following the GA. Frailty, vulnerability in nutrition, poor performance status and higher CARG chemotherapy toxicity prediction score were predictive for shorter survival.